Since CRISPR/Cas9 technology has been already explored for multiplexing editing of a combinatorial set of genomic sites in T cells [42], we initially tested our CRISPR/Cas9 approach for simultaneous editing of PD-1, LAG-3, and TIM-3 on the T cell lymphoma cell line EL4 and then on primary T cells. Here, HAVCR2 is linked to T-cell non-Hodgkin lymphoma.